Dr. Reddy's Laboratories Limited (RDY) Q4 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A session reveal strong financial performance, product development, and market expansion strategies. Despite some challenges, such as lower gross margins and the wind-down of CAR-T investments, the company's optimistic guidance, new product launches, and market share gains indicate positive sentiment. The focus on emerging markets and sustainability goals further supports a positive outlook. The Q&A insights align with the earnings call, reinforcing the positive sentiment, especially with the expected growth in biosimilars and semaglutide. Therefore, the stock price is likely to experience a positive movement of 2% to 8%.
Key Financial Performance
Adjusted Revenue (Q4 FY '26) INR 7,969 crores (USD 849 million), a decline of 6% year-over-year and 9% quarter-over-quarter. The decline was primarily due to lower lenalidomide sales.
Adjusted Revenue (Full Year FY '26) INR 34,046 crores (USD 3.63 billion), representing a growth of 4.6%. Growth was driven by double-digit growth in the base business, excluding lenalidomide.
Gross Margin (Q4 FY '26) 48%, lower by 760 basis points year-over-year and 615 basis points sequentially. Decline due to lower lenalidomide sales and price erosion in unbranded generics.
Gross Margin (Full Year FY '26) 53.5%, lower by 498 basis points year-over-year. Decline due to lower lenalidomide sales and price erosion in unbranded generics.
SG&A Expenses (Q4 FY '26) INR 2,662 crores, an increase of 11% year-over-year and 1% sequentially. Increase due to targeted investments in branded franchise and acquired NRT Consumer Healthcare business.
SG&A Expenses (Full Year FY '26) INR 10,435 crores, an increase of 11% year-over-year. Increase due to targeted investments in branded franchise and acquired NRT Consumer Healthcare business.
R&D Spend (Q4 FY '26) INR 541 crores, a decrease of 26% year-over-year and 12% sequentially. Decrease reflects reduced biosimilars developmental expenditure.
R&D Spend (Full Year FY '26) INR 2,385 crores, a decrease of 13% year-over-year. Decrease reflects reduced biosimilars developmental expenditure.
EBITDA (Q4 FY '26) INR 1,554 crores (USD 166 million), a decline of 37% year-over-year and 28% sequentially. Decline due to lower lenalidomide sales and one-off items.
EBITDA (Full Year FY '26) INR 8,419 crores (USD 897 million), reflecting a margin of 24.7% on adjusted revenue base.
Profit Before Tax (Q4 FY '26) INR 994 crores (USD 106 million), representing a margin of 12.5%. Adjusted for one-off items.
Profit Before Tax (Full Year FY '26) INR 6,463 crores (USD 689 million), representing a margin of 19%. Adjusted for one-off items.
Profit After Tax (Q4 FY '26) INR 220 crores (USD 23 million), a margin of 2.9% on reported revenues.
Profit After Tax (Full Year FY '26) INR 4,285 crores (USD 457 million), a margin of 13% before adjusting for one-off items.
Operating Working Capital (March 31, 2026) INR 14,434 crores (USD 1.54 billion), an increase of INR 2,920 crores (USD 311 million) over December 31, 2025.
CapEx Cash Outflow (Q4 FY '26) INR 438 crores (USD 47 million).
CapEx Cash Outflow (Full Year FY '26) INR 2,302 crores (USD 245 million).
Free Cash Flow (Q4 FY '26) INR 600 crores (USD 64 million).
Free Cash Flow (Full Year FY '26) INR 2,004 crores (USD 214 million).
Net Cash Surplus (March 31, 2026) INR 3,271 crores (USD 349 million).
North America Generics Revenue (Q4 FY '26) USD 199 million, a decline of 40% year-over-year and 26% sequentially. Decline due to lenalidomide sales and one-time shelf stock adjustment.
North America Generics Revenue (Full Year FY '26) USD 1.3 billion, a decline of 21% year-over-year. Decline due to lenalidomide sales.
Emerging Markets Revenue (Q4 FY '26) INR 1,806 crores, a growth of 29% year-over-year and a decline of 5% sequentially. Growth driven by new product launches and higher volume.
Emerging Markets Revenue (Full Year FY '26) INR 6,761 crores, a growth of 23% year-over-year. Growth driven by new product launches and higher volume.
India Business Revenue (Q4 FY '26) INR 1,566 crores, a growth of 20% year-over-year and a decline of 2% sequentially. Growth driven by innovation franchise, new brand launches, price increase, and volume growth.
India Business Revenue (Full Year FY '26) INR 6,219 crores, a growth of 16% year-over-year. Growth driven by innovation franchise, new brand launches, price increase, and volume growth.
European Business Revenue (Q4 FY '26) USD 136 million, a decline of 3% year-over-year and sequentially. Decline due to price erosion in generics.
European Business Revenue (Full Year FY '26) USD 542 million, a growth of 37% year-over-year. Growth driven by acquisition-led growth in nicotine replacement therapy.
PSAI Business Revenue (Q4 FY '26) USD 101 million, a decline of 10% year-over-year and a growth of 10% sequentially. Decline due to lower API volume uptake.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Semaglutide Injection Approval: Dr. Reddy's became the first company to secure regulatory approval of semaglutide injection for type 2 diabetes in Canada and India. They launched the brand Obeda in India and received approval for an oral version of semaglutide in India.
Abatacept Biosimilar: The U.S. FDA accepted for review the BLA for the intravenous presentation of abatacept biosimilar candidate.
Hormone Replacement Therapy: Acquisition of Progynova and Cyclo-Progynova in India to strengthen the hormone replacement therapy segment.
Nicotine Replacement Therapy: Operational integration of the acquired consumer healthcare business in nicotine replacement therapy is largely complete.
Emerging Markets Growth: Revenue in emerging markets grew by 23% year-over-year, driven by new product launches and higher volumes.
India Market Performance: India business posted a 16% year-over-year growth in revenue, driven by innovation, new brand launches, price increases, and volume growth.
European Market Expansion: European business grew by 37% year-over-year due to acquisition-led growth in nicotine replacement therapy.
Cost Optimization: Continued focus on cost efficiencies and productivity improvements to achieve margins above 50% in FY '27.
Sustainability Achievements: Dr. Reddy's received a gold medal from EcoVadis and was ranked among the top 5% globally for sustainability.
Pipeline Development: Advancing key pipeline programs such as semaglutide and abatacept to drive future growth.
Inorganic Growth: Pursuing value-accretive inorganic opportunities to support sustainable long-term growth.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Shelf-stock adjustment (SSA) related to lenalidomide: A reduction in revenue of INR 453 crores due to SSA, impacting financial performance.
Potential VAT liability: An additional provision of INR 114 crores related to potential VAT liability in one subsidiary, impacting SG&A expenses.
Impairment charges: Impairment of INR 135 crores, including R&D charges for discontinuation of CAR-T therapy programs and INR 93 crores for discontinuation of a trial by a partner.
Price erosion in unbranded generics: Decline in gross margins due to price erosion in unbranded generics businesses.
Lower lenalidomide sales: Significant decline in revenue and gross margins due to reduced sales of lenalidomide.
Regulatory concerns in Brazil: Concerns raised by ANVISA regarding generic semaglutide filing, delaying market entry.
Price erosion in European generics: Decline in revenue in the European market due to price erosion in generics.
Lower API volume uptake: Decline in PSAI business revenue due to lower API volume uptake.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Base Business Growth: The base business is expected to sustain its growth momentum in FY '27.
Gross Margin Improvement: Margins are expected to improve and be above 50% in FY '27 due to focus on cost efficiencies and productivity improvement.
SG&A Spending: SG&A spending is expected to remain at the same level as FY '26 for the year ahead.
R&D Spending: R&D spending is projected to be in the range of 7% to 8% of adjusted revenues in FY '27.
Effective Tax Rate (ETR): The ETR is expected to be 24% to 25% for FY '27.
Product Launches: The company aims to continue its product launch momentum in FY '27, including semaglutide and abatacept.
Pipeline Development: Focus will remain on advancing differentiated pipeline programs such as semaglutide and abatacept.
Operational Efficiency: The company will drive operational efficiency and pursue value-accretive inorganic opportunities.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividend Payment: The Board recommended payment of a dividend of INR 8 per equity share of face value of INR 1 each. This is equivalent to 800% of the face value for the year ended March 31, 2026, subject to approval of the shareholders of the company.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Why was the shelf stock adjustment for REVLIMID so large this quarter?
A:The CEO, Erez Israeli, stated that the company was surprised by the large adjustment, attributing it to planning issues or mistakes on the customers' end.
Q:What is the competitive landscape for semaglutide now that approvals have been granted in Canada?
A:Erez Israeli mentioned that the current landscape includes Novo Nordisk and two other players, with additional competitors likely to enter in the coming months. The Canadian market is divided into public, private, and cash segments, and the reimbursement price is expected to evolve over time.
Q:Are you still confident in achieving 12 million units of semaglutide sales by FY '27 despite setbacks in Brazil?
A:Erez Israeli expressed confidence in the 12 million units target but noted a delay of several months, potentially pushing some sales into FY '28. For the period until the end of calendar '26, the estimate is 6-7 million units.
Q:What is the pricing strategy for semaglutide in Canada and other markets?
A:The list price in Canada will be about half of Novo Nordisk's price, with net prices ranging from $25 to $30 per unit, depending on competition. Prices in some markets may be higher.
Q:What are the plans for SG&A spending in FY '27?
A:SG&A spending is expected to remain at similar nominal levels as FY '26, with investments in NRT, innovative product launches in India and emerging markets, and productivity initiatives. As sales grow, SG&A as a percentage of sales is expected to decrease.
Q:Why were gross margins lower this quarter, and what is the outlook?
A:Gross margins were at 48% due to product mix impacts. The company expects margins to return to the 50-55% range, driven by cost improvements, new product launches, and product mix changes.
Q:What is the growth outlook for the U.S. market excluding lenalidomide?
A:The company expects double-digit growth in North America excluding lenalidomide, supported by new product launches and market share gains.
Q:What is the status of denosumab and abatacept?
A:Denosumab is set to launch in Europe, with U.S. approval pending. Abatacept IV has been accepted for review and is on track for a potential launch in early calendar '27, pending FDA inspection.
Q:Why did the company wind down its CAR-T investments?
A:The company invested INR 135 crores in CAR-T but faced clinical issues, leading to a decision to deprioritize and impair the investment.
Q:What is the current size and profitability of the biosimilar business?
A:The global biologics sales are above $100 million but are not yet profitable due to ongoing investments. Profitability is expected post-abatacept launch, potentially by FY '28.
Q:What is driving growth in the NRT business, and is it sustainable?
A:Growth has been stronger than expected, driven by customer stock transitions. Sustainable growth is expected to be in the high single-digit to low double-digit range.
Q:What is the penetration of semaglutide in India?
A:The company has achieved a market share of over 10% in India and expects further growth with the launch of an oral product.
Q:Why was there a sequential decline in U.S. revenues despite new product launches?
A:The decline was attributed to buying patterns of customers rather than market share loss or price erosion. The adjusted Q4 sales are considered a base for future growth.
Q:What are the expectations for semaglutide approvals and sales in Brazil and other markets?
A:Approval in Brazil is expected with a delay of 3-4 months. The company plans to launch in over 50 markets in the current calendar year and over 80 in the next 12 months, with a target of 10-11 million pens sold.
Q:Are there any large product opportunities in the U.S. generics market for FY '27?
A:Bosutinib is identified as a potential significant product, but most launches are expected to be competitive.
Q:What is the expected split between direct sales and partner sales for semaglutide?
A:The split is estimated to be approximately 50-50 between direct sales and partner sales.
Q:What is the growth outlook for the U.S. business excluding semaglutide?
A:The U.S. business is expected to grow in double digits excluding semaglutide, supported by biosimilars, consumer health, and 505(b)(2) products.
Q:What is the margin outlook for the business with and without semaglutide?
A:The base business margin is expected to remain around 20%, with semaglutide potentially increasing it closer to 25%, depending on sales volume and pricing.
Q:What is the expected capacity for semaglutide pens by FY '28?
A:The company expects to have significant capacity, potentially exceeding 40 million pens, depending on demand.
Q:Has Novo Nordisk introduced an authorized generic (AG) for semaglutide in Canada?
A:The company assumes Novo Nordisk will introduce an AG but does not have specific knowledge of its current status.
Q:What is the expected annual biosimilar sales by FY '29?
A:Biosimilar sales are expected to reach $500-700 million, with abatacept being a significant contributor.
Q:What is the CapEx plan for the next two years?
A:The annual CapEx is expected to be around INR 2,000 crores, focusing on biosimilars, product-specific investments, and general CapEx.
Q:How will the FDA's draft guidelines impact R&D costs for biosimilars?
A:R&D costs are expected to decrease due to the completion of abatacept Phase III trials, partnerships, and increased productivity through AI and other technologies.
Q:What is the outlook for semaglutide dosage forms in emerging markets?
A:The oral form is expected to grow in emerging markets, particularly in lower-priced regions, complementing pens and vials.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the shelf stock adjustment for REVLIMID, citing customer planning issues without elaboration. Additionally, they did not provide a clear answer on the technical reasons behind the CAR-T investment failure, only stating clinical issues. The CEO also avoided giving a precise timeline for denosumab approval in the U.S. and was vague about the impact of Novo Nordisk's potential authorized generic in Canada.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CAR
ETR FY
FY ETR
FY INR
FY cash
FY decrease
Healthcare generic
Impairment INR
MVN
Number
SSA
USD FY
USD INR
USD decline
USD margin
VAT liability
account discontinuation
account lenalidomide
biosimilars expenditure
comparison period
court provision
crore FY
crore INR
crore USD
crore decrease
decrease biosimilars
decrease margin
decrease revenue
expenditure portion
generic spend
income INR
increase account
investment spend
item
labor court
lenalidomide sale
margin spend
portion investment
provision INR
revenue decrease
spend level
RDY Transcript
Dr. Reddy's Laboratories Limited (RDY) Q4 2026 Earnings Call Transcript
Positive5-12
The earnings call summary and Q&A session reveal strong financial performance, product development, and market expansion strategies. Despite some challenges, such as lower gross margins and the wind-down of CAR-T investments, the company's optimistic guidance, new product launches, and market share gains indicate positive sentiment. The focus on emerging markets and sustainability goals further supports a positive outlook. The Q&A insights align with the earnings call, reinforcing the positive sentiment, especially with the expected growth in biosimilars and semaglutide. Therefore, the stock price is likely to experience a positive movement of 2% to 8%.
Dr. Reddy's Laboratories Limited (RDY) Q3 2026 Earnings Call Transcript
Positive1-21
The earnings call highlights strong revenue growth, successful product launches, and strategic collaborations, particularly in the Indian market. Despite a decline in PAT, the company maintains a robust cash position and expects sustainable growth. The Q&A reveals optimism about innovative products and market expansion, though there are some uncertainties in biosimilar timelines. Overall, the positive developments, particularly in India, and optimistic guidance outweigh the negatives, suggesting a positive stock price movement.
Dr. Reddy's Laboratories Limited (RDY) Q2 2026 Earnings Call Transcript
Unknown10-24
The earnings call reveals mixed aspects: stable financial health with strategic R&D investments and promising biosimilar launches, but concerns over competitive pressures and legal challenges. Strong growth in India and emerging markets is positive, but price erosion in the U.S. and unclear guidance on semaglutide pricing impact sentiments. Given these balanced positives and negatives, a neutral stock reaction is expected.
Dr. Reddy's Laboratories Limited (RDY) Q4 2025 Earnings Call Transcript
Unknown5-9
Financial performance is mixed with strong EBITDA growth but declining annual EBITDA margin. Concerns include rising expenses, unclear tariff impacts, and competitive pressures on semaglutide. Positive aspects are stable US price erosion and strong US business growth. Management's lack of clarity on tariffs and severance costs adds uncertainty. Overall, the mixed signals suggest a neutral stock price movement.
RDY Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
